In addition, in the last case, not only is the BRAF status not always representative of the current status, but when the primitive tumor is a thin melanoma, the number of neoplastic cells may not be enough for the assessment of BRAF mutation with classical extractive methods. The gene discussed is BRAF; the disease is neoplasm.